POEMs

PCI Has More Benefits and Harms Than CABG for Selected Patients with Left Main Coronary Artery Disease

 

Am Fam Physician. 2017 Apr 1;95(7):455a-456.

Clinical Question

For selected patients with left main coronary artery disease, is percutaneous coronary intervention (PCI) with a drug-eluting stent an option to replace coronary artery bypass grafting (CABG)?

Bottom Line

The authors of this study—which was sponsored by a manufacturer of stents—argue that the results prove that PCI is just as good as CABG for many patients with a left main lesion. A deeper dive into the data suggests that it is not quite so clear. Patients undergoing PCI had fewer early myocardial infarctions, but more later deaths and later myocardial infarctions. There are other benefits to PCI, including shorter hospital stay, lower cost, and faster recovery. But patients should be informed of the tradeoffs, and it is important to look at longer-term outcomes beyond three years (which the investigators promise to do). (Level of Evidence = 1b)

Synopsis

Guidelines in Europe and the United States continue to recommend CABG as the preferred treatment for all patients with left main coronary artery disease. However, subgroup analyses in previous trials suggest that some patients may do just as well with a drug-eluting stent. This study included 1,905 patients with left main coronary artery disease (defined as at least 70% stenosis, or 50% to 70% stenosis judged to be hemodynamically significant) and low to intermediate anatomic complexity (SYNTAX score < 32). The patients were randomized to receive CABG or PCI with a drug-eluting stent. The average age of participants was 66 years, 77% were men, 91% were white, 56% lived in Europe, and 39% lived in the United States. Approximately 29% had diabetes mellitus, 15% had experienced a recent myocardial infarction, 17% had a previous PCI, and 16% had renal insufficiency. The primary end point was a composite of death, stroke, or myocardial infarction at three years. Groups were similar at the start of the study, and analysis was by intention to treat. This study was designed as a noninferiority trial, defining &#x

POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, Associate Deputy Editor.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

 

 

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 15, 2017

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article